Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …

Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …

Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly.
The standard of care has changed little over the previous four decades, and survival rates …

Osteosarcoma (OS) and Ewing sarcoma (ES) are the two most common types of primary
bone cancer, which mainly affect children and young adults. Despite intensive multi-modal …

Introduction: Bone sarcomas are rare malignancies and once advanced, there is limited
response to current chemotherapeutic regimens. Targeted therapies could have substantial …

Osteosarcoma (OS) is a mesenchymal-origin tumor that constitutes the most common
primary malignant bone tumor. The survival rate of the patients has significantly improved …

Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the
2000s. These cancers presented challenges in new drug development partly because of …

Abstract Background Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib
have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in …

Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases
which occur mainly in adolescents and young adults. With the current therapies, some …

The primary conclusions of our 2014 contribution to this series were as follows: Multiple
receptor tyrosine kinases (RTKs) likely contribute to aggressive phenotypes in …